SCHEMBL6998639

SCHEMBL6998639

COc1ccc(CNCc2ccc3c(c2)NC(=O)C(C)O3)cc1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.76
HSD17B10 Q99714 1/20 0.47
POLB P06746 2/20 0.45
HTR1A P08908 2/20 0.45
HTR7 P34969 2/20 0.45
KCNH2 Q12809 1/20 0.45
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
USP2 O75604 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302991 0.91 PARP1 (0.90) PARP1POLBGAAUSP2SMN1; SMN2
SCHEMBL6999385 0.90 PARP1 (0.75) PARP1HTR1AHTR7KCNH2ALDH1A1
SCHEMBL532477 0.86 PARP1 (1.00) PARP1HSD17B10POLBSMN1; SMN2
SCHEMBL7003151 0.86 PARP1 (0.81) PARP1POLBGAAUSP2SMN1; SMN2
SCHEMBL6303081 0.85 PARP1 (0.80) PARP1POLBGAAUSP2SMN1; SMN2
SCHEMBL6999731 0.85 PARP1 (0.80) PARP1HSD17B10POLBALDH1A1USP2
SCHEMBL6995652 0.85 PARP1 (0.80) PARP1POLBLMNASMN1; SMN2MEN1
SCHEMBL6305288 0.85 PARP1 (0.88) PARP1HSD17B10POLBMAPTSMN1; SMN2
SCHEMBL6310170 0.84 PARP1 (0.95) PARP1HSD17B10POLBSMN1; SMN2
SCHEMBL6989623 0.84 PARP1 (0.78) PARP1HSD17B10POLBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed